IBIO iBio, Inc.

NASDAQ
$1.26

iBio, Inc. (IBIO) is expected to report earnings on November 27, 2026, before the market open. The consensus earnings estimate is a loss of $0.06 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.3% since its last earnings release on August 28, 2026.

iBio Beat Consensus Estimates
Friday, August 28, 2026 · 7:00 AM ET
Earnings Date
1st Quarter, Sep 2026
Nov 27
Friday · 7:00 AM ET
Earnings Whisper
-
vs ($0.06)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.26

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About iBio, Inc.

Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture of proteins applicable to a range of disease agents, such as influenza, sleeping sickness, anthrax, plague, human papillomavirus and veterinary influenza applications. IBio, Inc. is headquartered in Newark, Delaware.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.